Ginkgo Bioworks Holdings Inc. (DNA) stock plummeted 5.05% in pre-market trading on Thursday after reporting disappointing 2024 full-year earnings results.
The biotech company reported a net loss of $547 million for the fiscal year 2024, although this represented a 39% narrowing from the previous year. However, revenue declined by 9.7% year-over-year to $227 million, missing analyst expectations.
Looking ahead, Ginkgo Bioworks projected an average revenue decline of 2.5% per year over the next three years, underperforming the expected 4.4% growth for the broader US chemicals industry. The company's shares have fallen 28% over the past week, reflecting investors' concerns about its financial performance and growth prospects.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。